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& Abstract
Objective: Evaluate prevalence and risk-adjusted healthcare
costs of diagnosed opioid abuse in the national Veterans
Health Administration (VHA). Costs were compared between
patients with and without diagnosed opioid abuse.
Design: Medical and pharmacy claims analysis of VHA data
(10/01/2006 to 09/30/2010) were retrospectively analyzed.
Prevalence was calculated as the percent of patients with
diagnosed opioid abuse for the entire VHA membership and
those with noncancer pain diagnoses, compared between
patients prescribed opioids prior to abuse diagnosis and
those not prescribed opioids through the VHA system.
Healthcare utilization and costs were estimated using
matching techniques and generalized linear models to
control for clinical and demographic differences between
patients with and without diagnosed opioid abuse. Sepa-
rate comparisons were made (with diagnosed abuse vs.
without) for each cohort: patients with/without opioid
prescriptions.
Results: Five-year diagnosed opioid abuse was 1.11%.
Among patients prescribed opioids, 5-year abuse prevalence
was 3.04%. Pain patients prescribed opioids had the highest
abuse rate at 3.26%. Adjusted annual healthcare costs for
diagnosed opioid abuse patients were higher than for
those without diagnosed abuse, (prescribed opioids overall
healthcare costs: $28,882, with diagnosed abuse vs. $13,605
for those without; not prescribed opioids: $25,197 vs. $6350,
P-value< 0.0001; opioid-specific healthcare costs for patients
prescribed opioids: $8956 vs. $218; patients not prescribed
opioids: $8733 vs. $20).
Conclusions: Diagnosed opioid abuse prevalence is almost
7-fold higher in the veteran’s administration population
than in commercial health plans and translates to a signifi-
cant economic burden. Appropriate interventions should be
considered to prevent and reduce opioid abuse. &
Key Words: opioid abuse, opioid dependence, healthcare
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INTRODUCTION
Over the past decade, there has been an increase in
opioid prescriptions to treat cancer-related and non-
cancer pain, and a parallel increase in opioid abuse.1 In
2007, there were 12.7 million nonmedical opioid users
in the United States.2 When McAdam-Marx et al.3
studied the relationship between diagnosed opioid
abuse/dependence in Medicaid patients and economic
outcomes from 2002 to 2003, the total adjusted cost of
patients with diagnosed abuse/dependence significantly
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exceeded the cost for matched controls ($23,556 vs.
$8663; P < 0.001). Many recent studies on the cost
burden of diagnosed opioid dependence and abuse
disorders have limitations in sample size, data range,
and data quality.4,5 The Veterans Health Administra-
tion (VHA) is the largest integrated healthcare system
in the United States, providing care to over 8.3 million
veterans every year. A recent study demonstrated
that the VHA population contains a large number of
prescribed opioid users, of which 27,000 were diag-
nosed as opioid dependent in 2007.6 However, the
prevalence and economic burden of diagnosed opioid
abuse, which is different than opioid dependence, in
the VHA population have not been described. To our
knowledge, no previous research has estimated the
prevalence of diagnosed opioid abuse and economic
outcomes including all-cause and opioid-related health-
care utilization and costs among VHA beneficiaries
with and without diagnosed opioid abuse.
METHODS
This study used VHA administrative claims data from
October 2005 to September 2010 using the VHA
Medical SAS datasets (SAS version 9.3 software, Cary,
NC, USA). This dataset consists of national administra-
tive data for VHA-provided healthcare utilized primar-
ily by veterans and a small number of nonveterans
(eg, employees, eligible family members, research par-
ticipants) and includes inpatient, outpatient, laboratory,
pharmacy, radiology, vital signs, enrollment, and vital
status information. The frequency of diagnosed opioid
abusewas determined during the study period ofOctober
1, 2005 to September 30, 2010. Because only the first 3
quarters of the 2010 data were available, 2010 data were
weighted to extend to the entire year. To compare
healthcare utilization and costs, the identification period
was from October 1, 2006 to September 30, 2009.
Study Sample
The prevalence of diagnosed opioid abuse in patients
prescribed an opioid (prescription opioid receipt) and
patients who did not receive an opioid prescription
through the VHA system (no prescription opioid
receipt) during the study period, and noncancer pain
patients, was determined in subjects 12 years of age or
older from October 1, 2005. Prescribed opioid users
were required to have at least one pharmacy claim for
opioids in the VA setting during the study period,
while study eligible opioid nonusers had no opioid
pharmacy claims in the VHA setting during the study
period. Noncancer pain patients must have received at
least one medical claim for a noncancer pain diagnosis
during the entire study period. Opioid abuse was
defined using the following diagnoses: International
Classification of Diseases 9th Revision Clinical Mod-
ification (ICD-9-CM) codes: 304.0x (opioid type
dependence), 304.7x (combinations of opioid abuse
with any other), 305.5x (opioid abuse), 965.00,
965.02, 965.09 (poisoning by opiates and related
narcotics, not heroin). We used the same codes used
by other authors in their analyses to enable better
comparison between studies.7,8
To compare healthcare utilization and costs
between diagnosed opioid abusers and those without
diagnosed abuse, subjects with an opioid abuse
diagnosis were required to have at least one medical
claim for opioid abuse using the same sets of ICD-9-
CM described above during the identification period
(10/01/2006 to 09/30/2009). The date of the first such
claim was designated as the index date. For patients
without diagnosed opioid abuse claims, the index date
was randomly assigned during the identification
period to avoid selection bias. All patients were
required to be 12 years or older on the index date.
Minors under the age of 18 were considered in thus
study due to previously published literature indicating
the burden of opioid use in this age cohort, and their
availability in the VHA dataset may be explained
through coverage of TRICARE and CHAMPVA-eligi-
ble dependents.4,9 All patients must also have contin-
uous enrollment in a health plan with medical and
pharmacy benefits 12 months pre-index date (baseline
period) to 12 months postindex date (follow-up
period).
Cohort Assignments (For Healthcare Costs and
Comparisons Only)
Two cohorts were created to compare healthcare
resource use and costs between those with and without
diagnosed opioid abuse. The Diagnosed Opioid Abusers
Cohort consisted of patients with at least one medical
claim for the codes described above during the follow-up
period. The Opioid nonabusers Cohort comprised of
patients with no medical claims for the codes described
above during the follow-up period. Outcomes for the
two cohorts were further compared separately, by those
who received or did not receive an opioid prescription.
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Covariates and Outcome Variables
Covariate factors included gender, age, age group,
region, race, marital status, pre-index Charlson Com-
orbidity Index (CCI) Score10,11 pre-index Chronic Dis-
ease Score (CDS), nonpain-related and pain-related pre-
index comorbid conditions, and overall and opioid-
related healthcare utilizations and costs.
Nonpain-related pre-index comorbidity conditions
included other substance abuse, nonopioid poisoning,
psychiatric disorders, human immunodeficiency virus/
acquired immune deficiency syndrome (HIV/AIDS),
endocarditis, skin infections/abscesses, gastrointestinal
bleeding, cirrhosis/chronic or acute liver disease, hepa-
titis A, B, C, alcoholic hepatitis, other hepatitis,
pancreatitis, sexually transmitted disease, herpes sim-
plex, burns, trauma, and motor vehicle accidents. Pain-
related pre-index comorbid conditions included cancer,
low back pain, other back/neck disorders, arthritis,
neuropathic pain, fibromyalgia, and headache/migraine.
Each covariate was assessed during the 12-month
baseline period.
Outcome Variables
Outcome variables included the prevalence of diagnosed
opioid abuse, healthcare utilization and costs. Diag-
nosed opioid abuse prevalence was calculated for all
patients, prescription opioid users and patients without
prescription opioid receipt, and chronic noncancer pain
patients. To calculate the prevalence rate, the number of
patients with diagnosed opioid abuse during the study
period was divided by the total number of patients in the
population of interest.
Consumer Price Index (CPI)-adjusted postindex total
healthcare costs were computed as the combined health
plan and patient-paid amounts in the postindex period
for all medical and pharmacy claims including all-cause
and opioid-related total healthcare, inpatient, outpa-
tient, office and emergency room (ER) visit, and phar-
macy costs. Costs were adjusted to June 2010 U.S.
dollars using the CPI medical care component. Opioid-
related claims were defined as inpatient and outpatient
claims with opioid diagnosis at any position, or phar-
macy claims for an opioid prescription.
The number of all-cause and opioid-related inpatient
admissions and outpatient, office, and ER visits was
calculated for each patient. The number of hospital-
ization days was calculated during the postindex
period.
Statistical Analysis
Descriptive analyses were performed for baseline and
outcome variables. Percentages and standard deviations
were calculated for dichotomous variables, and P-values
were calculated using the chi-square test. Means and
standard deviations were calculated for continuous
variables, and P-values were calculated using the
Student t-test.
The prevalence of diagnosed opioid abuse was
calculated as the number of diagnosed opioid abusers
divided by the total number of individuals for the study
period of interest and was reported as a percentage and
as cases per 1000 person population.
Multivariate analysis was performed using both
propensity score matching (PSM) and generalized linear
model (GLM) techniques. Propensity scores were esti-
mated via unconditional logistic regression analysis.
Potential predictors of an opioid abuse diagnosis were
used as independent variables, and opioid abuse diag-
nosis was the outcome. Patients were matched if their
propensity scores were within  0.01 units of one
another.
Covariates in the logistic regression model included
the following variables: age, gender, region, race,
marital status, baseline CCI score, baseline CDS,
baseline comorbid conditions (non-pain-related, pain-
related), baseline healthcare utilization (all-cause,
opioid-related), and baseline healthcare costs (all-cause,
opioid-related). The dichotomous dependent variable
was diagnosed opioid abuse vs. nonabuse. To estimate
total costs, GLM with a gamma distribution and log
link function was used. In these models, the dependent
variables were total and opioid-related healthcare costs
such as inpatient and outpatient ER, office visit, total
and pharmacy costs. Independent variables were demo-
graphic and clinical factors used in PSM, and a group
variable (diagnosed opioid abuse vs. no diagnosed
abuse).
RESULTS
Overall Prevalence of Diagnosed Opioid Abuse
The overall 5-year prevalence of diagnosed opioid abuse
among the VHA population was 1.11% (Table 1).
Among patients prescribed an opioid, the overall prev-
alence of diagnosed opioid abuse was substantially
higher at 3.04%. The prevalence of diagnosed opioid
abuse was relatively low (0.29%) among patients who
had not received an opioid prescription. For patients
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with noncancer pain, the overall abuse rate was 1.98%,
slightly higher than the overall rate of 1.11%. When
pain patients were separated into prescription opioid
users and patients without prescription opioid receipt,
the rates of abuse were also slightly higher than overall
prescription opioid users and those without prescription
opioid receipt: 3.26% for opioid users and 0.54% for
patients without prescription opioid receipt.
Over 5 years, the prevalence of diagnosed opioid
abuse in noncancer pain patients (1.98%) was greater
than in patients without noncancer pain (0.27%). The
annual overall prevalence of diagnosed abuse in VHA
enrollees consistently increased over the 5-year study
period from 0.48% in 2006 to 0.73% in 2010
(Figure 1). For patients who had been prescribed an
opioid, the annual prevalence increased from 1.67% to
2.10% before slightly decreasing in 2010 to 1.80%. In
patients who had not received an opioid prescription,
diagnosed opioid abuse remained fairly constant,
ranging from 0.25% in 2006 to 0.27% in 2010.
In the first year (2006), diagnosed opioid abuse
prevalence for the entire VHA population was the
highest for patients 35 to 54 years of age (1.26%) and
the lowest for patients age 65 and older (0.05%)
(Figure 2). Diagnosed opioid abuse prevalence had the
greatest increase over the study period from 2006 to
2010 for patients between the ages of 18 to 25 (0.38% to
1.09%) and 26 to 34 (0.45% to 1.18%). Patients 35 to
54 years of age maintained the highest percentage of
diagnosed opioid abusers from 2006 to 2010. Among
patients prescribed an opioid, the prevalence of diag-
nosed abuse was the highest among patients between age
35 and 54 years (3.39%) (Figure 3). However, by 2010,
patients between ages 26 to 34 had the highest
diagnosed abuse rate among opioid users at 3.90%.
For patients who had not received an opioid prescrip-
tion, the 35- to 54-year-old patient group also had the
highest diagnosed abuse rate (0.70%) compared to
the other age groups. Patients age 35 to 54 maintained
the highest percentage of diagnosed opioid abusers in all
5 years of the study.
Patients prescribed an Opioid: Demographic/Clinical
Characteristics
The following paragraphs summarize the demographic
and clinical characteristics of patients who had been
Table 1. Five-Year Overall Prevalence of Prescribed Opi-
oid Diagnosed Abuse in VHA Enrollees (Pain Patients,
Prescribed Opioid Users and Non Users)
Totals
Population
Sample
Size
Opioid
Abuser
Sample Size
Prevalence
(%)
VHA Enrollee 8,856,471 98,380 1.11
Prescription opioid user 2,631,511 80,066 3.04
Patients without
prescription opioid receipt
6,224,960 18,314 0.29
Noncancer pain patient 4,337,072 86,052 1.98
Noncancer pain + prescription
opioid user
2,304,181 75,069 3.26
Noncancer pain + patient
without prescription
opioid receipt
2,032,891 10,983 0.54
Patients without noncancer pain 4,519,399 12,328 0.27
VHA, veterans health administration.
Figure 1. Annual prevalence of diagnosed opioid abuse, disag-
gregated by prescription opioid use status
Figure 2. Annual prevalence of diagnosed opioid abuse in
overall population by age
Figure 3. Annual prevalence of diagnosed opioid abuse in
prescription opioid users by age
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prescribed an opioid and had diagnosed opioid abuse
(N = 28,403) and patients prescribed an opioid without
diagnosed abuse (N = 1,052,389).
Themeanageofprescribedopioiduserswithdiagnosed
opioid abuse was lower than patients without diagnosed
opioid abuse (52 vs. 61, P-value < 0.0001). Diagnosed
opioid abusers were more likely to be male (93.31% vs.
92.67%, P-value < 0.0001) and had a higher probability
of beingdivorced (37.66%vs. 25.91%,P-value< 0.0001)
nevermarried (21.65%vs. 14.32%,P-value < 0.0001) or
separated (3.47% vs. 0.19%, P-value < 0.0001) than
patients without diagnosed opioid abuse. A higher
percentage of diagnosed opioid abusers were White
(52.46% vs. 48.63%, P-value < 0.0001), Black/African
American (18.42% vs. 12.30%, P-value < 0.0001), and
American Indian patients (0.77% vs. 0.63%, P-value
= 0.0034). The most prevalent comorbidities in the
diagnosed abuser group were psychiatric problems
(75.64%), other substance abuse (64.27%), arthritis
(59.47%), and low back pain (55.20%). However, in
terms of overall comorbidity measurements, patients
without diagnosed opioid abuse had a higher CCI
(1.34 vs. 1.10, P-value < 0.0001) and CDS score (6.46
vs. 5.98, P-value < 0.0001) than the diagnosed abuser
cohort.
In terms of healthcare costs during the baseline
period, total all-cause healthcare costs (inpatient, out-
patient, pharmacy) were $14,157 for patients without
diagnosed opioid abuse vs. $21,559 for diagnosed
opioid abusers (P-value < 0.0001). The outpatient cost
for diagnosed abusers ($11,192) and patients without
diagnosed abuse ($8108) had the greatest impact on the
total average healthcare expenses.
Differences in Healthcare Utilization
We first estimated the unadjusted baseline and follow-
up differences and PSM-matched outcomes for opioid
users. Unadjusted baseline results revealed a signifi-
cantly higher percentage of diagnosed opioid abusers
who visited inpatient (34.45% vs. 18.01%, P-value
< 0.0001) and outpatient ER settings (34.69% vs.
20.14%, P-value < 0.0001) when compared to patients
without diagnosed opioid abuse. While nearly every
patient utilized outpatient pharmacy services, patients
without diagnosed opioid abuse were more likely to visit
the outpatient pharmacy than diagnosed opioid abusers
(99.70% vs. 99.28%, P-value < 0.0001).
After PSM, 28,142 patients from each cohort were
matched and GLM adjustments were made to compare
follow-up healthcare utilization and costs between
diagnosed opioid abusers (Figure 4) and patients
without diagnosed abuse with only slight differences in
magnitude from the unadjusted results. However, the
sign and significance of the estimates do not change from
the unadjusted to the final PSM and GLM adjusted
results. Diagnosed abusers had higher healthcare
resource utilization that was statistically significant.
Patients with diagnosed abuse used follow-up care more
often than patients without diagnosed abuse and had
greater opioid-related follow-up healthcare utilization
and costs as well.
Diagnosed opioid abusers had a higher percentage of
inpatient and outpatient hospital visits than patients
without diagnosed opioid abuse (53.39% vs. 17.06% for
inpatient visits; 99.99% vs. 99.52% for outpatient visits;
all P-values < 0.0001). Diagnosed abusers were also
more likely to have outpatient ER visits compared to
patients without diagnosed abuse (21.5% vs. 10.55%,
P-value < 0.0001). Follow-up opioid-related healthcare
utilization was also greater for diagnosed abusers com-
pared to patients without diagnosed abuse (35.94% vs.
0.15% for inpatient care, P-value < 0.0001).
Differences in Direct Healthcare Costs
All adjusted follow-up healthcare costs (all-cause and
diagnosed opioid abuse-specific) were significantly
higher in the diagnosed opioid abuser cohort than in
patients without diagnosed opioid abuse. In terms of the
all-cause costs, the average direct healthcare costs for
inpatient services nearly 4 times more expensive among
patients with diagnosed opioid abuse than nonabusers
($12,837 vs. $3436, P-value < 0.0001, Figure 5 and
Figure 4. Follow-up healthcare utilization of diagnosed opioid
abusers—generalized linear model (GLM) adjusted over propen-
sity score matching (PSM)
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Table 2). Outpatient pharmacy and nonpharmacy costs
were also higher for diagnosed opioid abusers. The
greatest difference in opioid abuse-specific costs between
diagnosed opioid abusers and patients without diag-
nosed opioid abuse occurred with inpatient visits ($9603
vs. $5, P-value < 0.0001). When all costs were aggre-
gated, total follow-up expenses for diagnosed abusers
averaged $28,882 compared to $13,605 for patients
without diagnosed opioid abuse. The average opioid-
related follow-up expenditure was $8956 for a pre-
scribed opioid abuser compared to $218 for a patient
without diagnosed opioid abuse (all P-values < 0.0001).
Patients without an Opioid Prescription (NonUser):
Clinical/Demographic Characteristics
The baseline demographic and clinical characteristics of
patients without an opioid prescription (n = 3,607,371),
including identified patients without diagnosed opioid
abuse (99.47%; n = 3,588,203) and diagnosed opioid
abusers (0.53%; n = 19,168), were similar to prescrip-
tion opioid users. Diagnosed opioid abusers were youn-
ger than patients without diagnosed abuse (51 vs. 63,
P < 0.0001). Nonusers with an opioid abuse diagnosis
were more likely to be male (95.35% vs. 92.79%) and
divorced (35.47% vs. 17.45%), never married (32.50%
vs. 12.94%) or separated (3.76% vs. 0.10%, all
P-values < 0.0001) compared to those without diag-
nosed abuse. A higher percentage of diagnosed opioid
abusers were Black/African American (28.64% vs.
8.55%, P-value < 0.0001) and American Indian
(0.55% vs. 0.38%, P-value < 0.0001). Diagnosed abus-
ers had a greater number of studied comorbidities, with
psychiatric (55.26% vs. 22.94%, P-value < 0.0001),
other substance abuse problems (55.31% vs. 13.60%,
P-value < 0.0001), and hepatitis A, B, or C (19.17% vs.
1.63%, P-value < 0.0001) being the most common.
However, patients without diagnosed abuse had a higher
frequency of cancer (7.25% vs. 2.30%, P-value
< 0.0001) and higher overall comorbidity index scores,
such as CCI (0.74 vs. 0.54, P-value < 0.0001) and CDS
(3.73 vs. 2.77, P-value < 0.0001).
Baseline healthcare cost differences were also signif-
icant. The average total (inpatient, outpatient, phar-
macy) costs for patients without diagnosed abuse were
$3756 and $8209 (P-value < 0.0001) for diagnosed
abusers.
Differences in Healthcare Utilization
To determine the differences in healthcare utilization,
we first estimated the unadjusted baseline differences
and PSM-matched outcomes for patients without an
opioid prescription.
Similar to opioid user results, a significantly higher
percentage of diagnosed opioid abusers in the no
prescription receipt cohort visited outpatient ER
(20.58% vs. 6.55%, P-value < 0.0001), and inpatient
settings (16.39% vs. 2.93%, P-value < 0.0001) when
compared to patients without diagnosed abuse. How-
ever, those without diagnosed abuse utilized outpatient
services (office, other outpatient and outpatient phar-
macy) more frequently when compared to diagnosed
opioid abusers.
After PSM, 19,066 patients from each cohort were
matched and GLM modeling was performed for the
no prescription opioid receipt population. The final
estimates for healthcare utilization and costs for
Table 2. Follow-up Healthcare Costs for Diagnosed
Opioid Abusers-GLM adjusted over PSM
Follow-Up Healthcare Costs
Patients
without
Diagnosed
Opioid
Abuse
(N = 28,142)
Diagnosed
Opioid
Abusers
(N = 28,142)
P-valueDollars ($) Dollars ($)
Inpatient cost 3436 12,837 < 0.0001
Outpatient nonpharmacy cost 7801 13,062 < 0.0001
Outpatient pharmacy cost 1741 2209 <0.0001
Total follow-up costs 13,605 28,882 < 0.0001
Follow-up diagnosed opioid
abuse-specific healthcare costs
Inpatient cost 5 9603 < 0.0001
Outpatient nonpharmacy cost 2 2272 < 0.0001
Outpatient pharmacy cost 171 368 < 0.0001
Total follow-up costs 218 8956 < 0.0001
GLM, generalized linear model; PSM, propensity score matching.
Figure 5. Follow-up all-cause healthcare costs of prescribed
opoid users—generalized linear model (GLM)-adjusted over
propensity score matching (PSM)
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diagnosed opioid abusers and patients without diag-
nosed abuse are shown in Figure 6. There are slight
differences in magnitude compared to the unadjusted
tables. However, the significance of the estimates did not
change between the unadjusted and the final PSM- and
GLM adjusted results.
In both unadjusted and adjusted estimates, diagnosed
opioid abusers had statistically significant higher health-
care resource utilizations. They used follow-up care
more often than patients without diagnosed abuse and
had greater opioid-related follow-up healthcare utiliza-
tions and costs.
Within the group without prescription opioid receipt,
diagnosed abusers frequentedhospital servicesmore than
patients without diagnosed abuse (47.47% vs. 10.69%
for inpatient hospital visits, all P-values < 0.0001).
Differences in the number of outpatient and ER visits
were also statistically significant between the two groups.
Diagnosed opioid abusers had more outpatient visits
than patients without diagnosed abuse (99.97% vs.
97.13%, P-value < 0.0001) and were more likely to visit
the ER (18.5%vs. 6.20%,P-value < 0.0001). Follow-up
opioid-related healthcare utilization was also greater
for diagnosed abusers compared to patients without
diagnosed abuse (32.54% vs. 0.05% for inpatient care,
P-value < 0.0001).
Differences in Direct Healthcare Costs
Upon examination of the differences in direct healthcare
costs, the trend of healthcare received during the follow-up
period for patients without prescription opioid receipt was
parallel to the trend for those who received prescription
opioids (Figure 7, Table 3). The average total follow-up
healthcare cost was $6350 for patients without diagnosed
abuse, compared to $25,197 for diagnosed abusers
(P-value < 0.0001). The average total cost for opioid-
related follow-up healthcare was $8733 for diagnosed
opioid abusers compared to $20 for patients without
diagnosed opioid abuse (P-value < 0.0001).
DISCUSSION
This is the first study examining the prevalence and
economic cost of diagnosed opioid abuse using VHA
data. Two populations were studied as follows: patients
with and without an opioid prescription. Within each
group, we compared abuse prevalence, demographic
characteristics, hospital utilization, and treatment costs
for patients diagnosed with opioid abuse vs. patients
without diagnosed opioid abuse. Over the 5-year study
period, the overall prevalence of diagnosed opioid abuse
increased, reaching its highest rate in 2010 at 0.73% for
VHA enrollees. A similar study using MarketScan
commercial employee population data estimated the
Figure 6. Follow-up healthcare utilization of prescription opioid
use —generalized linear modelGLM-adjusted over propensity
score matching (PSM).
Figure 7. Follow-up healthcare costs of prescription opioid use—
generalized linear model (GLM) Adjusted over propensity score
matching (PSM)
Table 3. Follow-up Healthcare Costs for Prescription
Opioid Use-GLM Adjusted Over PSM
Follow-Up Healthcare Costs
Patients
without
Prescription
Opioid
Receipt
(N = 19,066)
Prescription
Opioid
Users
(N = 19,066)
P-valueDollars ($) Dollars ($)
Inpatient cost 1680 13,423 < 0.0001
Outpatient nonpharmacy cost 3864 10,723 < 0.0001
Outpatient pharmacy cost 593 1229 < 0.0001
Total follow-up costs 6350 25,197 < 0.0001
Follow-up diagnosed opioid
abuse-specific healthcare costs
Inpatient cost 5 7089 < 0.0001
Outpatient nonpharmacy cost 2 2851 < 0.0001
Outpatient pharmacy cost 10 127 < 0.0001
Total follow-up costs 20 8733 < 0.0001
GLM, generalized linear model; PSM, propensity score matching.
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overall prevalence of diagnosed opioid abuse at 0.12%
from 2008 to 2009,12 which is also consistent with the
0.11% prevalence rate from another commercial health
plan in the United States. Diagnosed opioid abuse
prevalence in the VHA population is almost 7 times
higher than the estimates from commercial data.
Both prescribed opioid users and patients without
prescription opioid receipt but with diagnosed opioid
abuse had higher all-cause healthcare costs and diag-
nosed opioid abuse-specific healthcare utilization and
costs, consistent with previous studies. A study by
McAdam-Marx et al.3 found that after matching diag-
nosed opioid abusers to nonabusers in the Medicaid
patient population, the mean annual cost for diagnosed
opioid abuse patients reached $23,556 vs. $8436 for
controls (P-value < 0.001). While the total follow-up
healthcare cost was higher in our study ($28,882 for
diagnosed abusers compared to $13,605 for nonabusers;
P-value < 0.001), the magnitude of difference in diag-
nosed abuse-related costs in the McAdam Marx et al.
study ($15,120) was similar to the difference in total
follow-up healthcare costs in this study ($15,277). In
patients without prescription opioid receipt, the differ-
ence in total follow-up healthcare was $25,197 for
diagnosed abusers vs. $6350 for patients without
diagnosed abuse (P-value < 0.001). Our study also
follows prior evidence that diagnosed opioid abuse
generally decreases as age increases.13 The average age
of prescribed opioid users with diagnosed opioid abuse
was significantly younger than patients without pre-
scription opioid receipt (52 vs. 62 years, P < 0.0001),
and the rate of increase among prescribed opioid
patients was greater among age groups 18 to 25 and
26 to 35, than for those over age 35.
While some VHA results agree with other national
studies using different datasets, it is important to
consider the implications of opioid use in the veteran
population alone. Previous research using VA regional
data has shown that prior substance abuse and mental
health disorders are two of the strongest predictors of
future opioid abuse.14 Investigating the specific costs
associated with diagnosed opioid abuse (eg, multiple
substance abuse, duration of drug abuse, and comor-
bidities) may reveal additional treatment patterns and
risk factors that lead to a substance abuse diagnosis.
Our study has several advantages over previous
research. We analyzed recent data from the VHA
database, a population with a high prevalence of
diagnosed opioid abuse. Both prescribed opioid users
and patients without prescription opioid receipt were
studied, and total healthcare costs as well as opioid-
related healthcare costs were examined.
There are limitations to consider that could potentially
affect the validity or interpretation of the results. Given
that the VHAMedical SAS datasets contain administra-
tive information from multiple inpatient and outpatient
sources, it is not specifically designed to capture a specific
disorder for research purposes. As a result, under-report-
ing or misclassification of health outcomes of interest may
occur. Although we used the same ICD-9-CM codes as
previous studies, the diagnosedabuse codes arenot specific
to “prescribed” opioid users. Errors in the data could have
resulted in an underreporting of patients with diagnosed
opioid abuse and could have imparted a conservative bias.
Errors in the electronic coding of complications can
introduce bias aswell.Opioids can potentially be obtained
from a friend or relative (diversion) or through illegal
activity,whichmayalso result indiagnosedabuse.The rise
in opioid prescriptions and diagnosed opioid abuse is
further complicated by the lack of physician preparedness
when diagnosing drug addiction or misuse. In the CASA
national survey of primary care physicians and patients, it
was revealed that less than one-third of doctors (30.2%)
felt prepared to diagnose prescription drug abuse.15
Because the incidence of diagnosed opioid abuse is often
much lower than the incidence of prescription drug abuse,
diagnosed drug abuse burden estimations are likely
underestimating total abuse outcomes.16 Finally, there is
the potential for confounding variables. Although the
models controlled for observable differences between
cohorts, there is always the possibility that other variables
(eg, socioeconomic status, treatment patterns, pain sever-
ity, prior abuse history, etc.) or factors such as disease
management programs, media exposure, and risk evalu-
ation and mitigation strategy (REMS) services could bias
the study estimates.
CONCLUSIONS
Diagnosed opioid abuse is a significant problem in the
VA population, and the annual prevalence rates of
diagnosed opioid abuse are almost 7 times higher than
other commercial health plans and still trending
upward. From an economic perspective, this continuing
increase is alarming because patients who abuse opioids
incur greater cost burden than patients without diag-
nosed opioid abuse. To our knowledge, this is the first
study to examine the healthcare burden and costs for
diagnosed opioid abusers in the national VHA popula-
tion. The study shows that patients with a diagnosis of
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opioid abuse have more than 2 times higher healthcare
costs than patients who do not have a diagnosis of
opioid abuse, regardless of whether the patients were
prescribed opioids or not.
The combination of recent data and new estimates of
the frequency and cost of diagnosed opioid abuse makes
these results relevant for future policy decisions. If
greater resources and intervention programs are not
devoted to addressing opioid abuse in the VA popula-
tion, economic costs will continue to increase as more
patients will require treatment for addiction and com-
orbidities linked to diagnosed opioid abuse.
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